ANI Pharmaceuticals Inc. (NASDAQ:ANIP) rose 5.2% during mid-day trading on Tuesday . The company traded as high as $70.79 and last traded at $70.49, with a volume of 144,433 shares trading hands. The stock had previously closed at $67.00.

ANIP has been the topic of a number of recent research reports. Citigroup Inc. upgraded ANI Pharmaceuticals to an “outperform” rating and set a $65.00 target price on the stock in a research note on Tuesday, July 19th. Guggenheim reiterated a “buy” rating and issued a $80.00 target price (up from $65.00) on shares of ANI Pharmaceuticals in a research note on Friday. Zacks Investment Research upgraded ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $67.00 target price on the stock in a research note on Wednesday, July 20th. Standpoint Research cut ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, May 24th. Finally, Raymond James Financial Inc. initiated coverage on ANI Pharmaceuticals in a research note on Wednesday, June 22nd. They issued a “strong-buy” rating and a $68.00 target price on the stock. Two investment analysts have rated the stock with a hold rating, four have issued a buy rating and three have given a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $64.00.

The stock has a market cap of $803.94 million and a PE ratio of 81.91. The stock has a 50-day moving average price of $57.79 and a 200-day moving average price of $45.02.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Thursday, August 4th. The specialty pharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.77 by $0.34. The firm had revenue of $31.30 million for the quarter, compared to the consensus estimate of $27.63 million. During the same quarter in the prior year, the firm posted $0.55 earnings per share. The business’s revenue for the quarter was up 60.5% on a year-over-year basis. On average, equities research analysts anticipate that ANI Pharmaceuticals Inc. will post $4.12 EPS for the current year.

A hedge fund recently raised its stake in ANI Pharmaceuticals stock. Mutual of America Capital Management LLC boosted its position in shares of ANI Pharmaceuticals Inc. (NASDAQ:ANIP) by 0.6% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 30,178 shares of the specialty pharmaceutical company’s stock after buying an additional 178 shares during the period. Mutual of America Capital Management LLC owned about 0.26% of ANI Pharmaceuticals worth $1,362,000 as of its most recent SEC filing.

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company’s focused areas of product development include anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.